NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ONCO
Onconetix, Inc.
There isn't enough reported data to score ONCO yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ONCO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ONCO's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
ONCO PE Valuation
ONCO has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ONCO Forward outlook
There aren't enough analyst estimates for ONCO to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the stronger earnings trend. Trailing diluted EPS is up 4.9% for NVO versus ONCO down 117%.
ONCO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$766,680.00 | +$3,828,845.00 |
| Q2 2025 | -$888,080.00 | +$4,109,920.00 |
| Q1 2025 | -$1,973,700.00 | +$2,293,300.00 |
| Q4 2024 | -$2,801,175.00 | +$921,825.00 |
| Q3 2024 | -$4,595,525.00 | -$2,923,041.56 |
| Q2 2024 | -$4,998,000.00 | -$3,393,516.56 |
| Q1 2024 | -$4,267,000.00 | -$2,407,516.56 |
| Q4 2023 | -$3,723,000.00 | -$1,853,000.00 |
ONCO is still losing money, but far less than before: $766,680.00 per share over the past year, against $4,998,000.00 at its worst in mid-2024.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over ONCO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over ONCO on profitability, with a higher operating margin.
ONCO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $17.1K | -84% |
| Q1 2026 | $21.5K | -79% |
| Q4 2025 | $303.6K | -57% |
| Q3 2025 | $303.7K | -25% |
| Q2 2025 | $106.5K | -85% |
| Q1 2025 | $101.6K | -75% |
ONCO's revenue has slid since its 2024 peak: $17,120 last quarter, down 84% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -15951% | -14134 points |
| Q1 2026 | -47657% | -35288 points |
| Q4 2025 | -422% | +3672 points |
| Q3 2025 | -681% | -31 points |
| Q2 2025 | -1817% | +114 points |
| Q1 2025 | -12369% | -9599 points |
| Q4 2024 | -4094% | N/A |
| Q3 2024 | -650% | N/A |
ONCO's operating margin was −15951% last quarter, down 14133 points from the same quarter a year ago, near the bottom of its range since 2024.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
ONCO has the stronger cash trend. Its trailing FCF is up 49% versus its history, compared with NVO at down 14%.
ONCO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$921.5K | +$3.4M |
| Q3 2024 | -$1.1M | +$1.9M |
| Q2 2024 | -$3.2M | -$1.4M |
| Q1 2024 | -$5.2M | -$788.7K |
| Q4 2023 | -$4.3M | -$1.5M |
| Q3 2023 | -$3M | -$1.2M |
| Q2 2023 | -$1.8M | +$1.4M |
| Q1 2023 | -$4.4M | -$3.6M |
ONCO has burned cash in almost every quarter: −$6M over the past year, against −$16M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over ONCO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ONCO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3468% | +218K shares |
| 1 year | +52301% | +224K shares |
| 3 years | +3203857% | +224K shares |
ONCO has 224,277 diluted shares, up 52301% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2023 | $25,527 |
| Q1 2023 | $33,454 |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ONCO Net Leverage
ONCO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ONCO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.5 | Oversold |
| Stochastic | 17.9 | Oversold |
ONCO's weekly RSI is 29 (oversold) and its Stochastic is 18 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ONCO PE vs Healthcare Sector
ONCO has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over ONCO on trend strength, trading above more of its moving averages.
ONCO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.05 | 50% below |
| 20 week MA | $7.26 | 58% below |
| 50 week MA | $229.4 | 99% below |
| 100 week MA | $3,385.0 | 100% below |
| 200 week MA | $414,179.2 | 100% below |
ONCO is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over ONCO on returns for 2026, with the stronger performance.
ONCO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $97,580,000.0 | $1,751,000.0 | -98% |
| 2023 | $1,751,000.0 | $336,600.0 | -81% |
| 2024 | $336,600.0 | $16,365.1 | -95% |
| 2025 | $16,365.1 | $715.0 | -96% |
| 2026 YTD | $715.0 | $3.03 | -100% |
ONCO has finished every year since 2022 lower, and it's down 100% so far in 2026.